Wall Street Zen Downgrades Teleflex (NYSE:TFX) to Sell

Teleflex (NYSE:TFX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other brokerages have also recently commented on TFX. Needham & Company LLC raised their target price on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a report on Monday, December 29th. Truist Financial upped their price target on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research report on Thursday, December 18th. Wells Fargo & Company raised their price objective on Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Finally, Zacks Research cut Teleflex from a “hold” rating to a “strong sell” rating in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $140.83.

Teleflex Stock Performance

Shares of NYSE TFX opened at $113.65 on Friday. Teleflex has a 12-month low of $100.18 and a 12-month high of $143.32. The firm has a market capitalization of $5.02 billion, a price-to-earnings ratio of -5.53, a price-to-earnings-growth ratio of 0.71 and a beta of 0.87. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81. The firm has a 50 day moving average of $110.97 and a 200 day moving average of $118.56.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing the consensus estimate of $3.73 by ($1.80). The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $912.57 million. Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The firm’s revenue was down 28.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.89 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, research analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Institutional Investors Weigh In On Teleflex

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Josh Arnold Investment Consultant LLC bought a new position in shares of Teleflex in the fourth quarter worth about $32,341,000. Invesco Ltd. raised its stake in Teleflex by 3.0% during the 4th quarter. Invesco Ltd. now owns 162,882 shares of the medical technology company’s stock valued at $19,878,000 after purchasing an additional 4,807 shares during the period. Alberta Investment Management Corp purchased a new position in Teleflex in the 4th quarter worth approximately $1,318,000. Vident Advisory LLC lifted its holdings in Teleflex by 2.8% in the 4th quarter. Vident Advisory LLC now owns 6,992 shares of the medical technology company’s stock worth $853,000 after purchasing an additional 188 shares in the last quarter. Finally, State of Tennessee Department of Treasury boosted its stake in Teleflex by 4.7% in the 4th quarter. State of Tennessee Department of Treasury now owns 22,374 shares of the medical technology company’s stock worth $2,731,000 after purchasing an additional 998 shares during the period. 95.62% of the stock is owned by institutional investors.

Key Stories Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Wolfe Research projects multi-year earnings recovery and growth for Teleflex, forecasting FY2027 EPS of $12.19 and continued expansion to $17.14 by FY2030 — a constructive long-term earnings trajectory if Teleflex executes. Wolfe Research model summary
• Neutral Sentiment: Wolfe issued detailed quarterly estimates (Q1–Q4 2026 and Q1–Q4 2027) to update models; these provide a clearer roadmap for quarterly cadence but do not by themselves change fundamentals. Analysts’ granularity may help set expectations ahead of upcoming quarters. Research note
• Negative Sentiment: Near-term concern: Wolfe’s FY2026 EPS of $8.25 sits well below the consensus cited in the filings (~$13.98) and contrasts with Teleflex’s prior FY2026 guidance (roughly $6.25–$6.55), highlighting forecast dispersion and uncertainty. This follows Teleflex’s most recent quarter where revenue and EPS missed expectations (quarterly revenue down ~28.5% YoY and a sizable EPS shortfall), which is weighing on the stock. Earnings and guidance details

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.